To include your compound in the COVID-19 Resource Center, submit it here.

Tofacitinib: Phase III data

Top-line data from a 1-year analysis of the ongoing, 2-year, double-blind Phase III ORAL Scan (1044) trial in 800 patients who had an inadequate response to methotrexate showed that twice-daily 10 mg oral tofacitinib met

Read the full 352 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE